Compare AXIL & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXIL | INCR |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4M | 50.4M |
| IPO Year | N/A | N/A |
| Metric | AXIL | INCR |
|---|---|---|
| Price | $6.47 | $0.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.9K | ★ 43.0K |
| Earning Date | 01-08-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $27,664,753.00 | ★ $72,158,312.00 |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | $39.24 | ★ N/A |
| Revenue Growth | ★ 4.18 | N/A |
| 52 Week Low | $4.04 | $0.68 |
| 52 Week High | $10.75 | $1.77 |
| Indicator | AXIL | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 44.79 |
| Support Level | $6.40 | $0.86 |
| Resistance Level | $6.83 | $0.96 |
| Average True Range (ATR) | 0.50 | 0.05 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 7.17 | 63.00 |
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, and outdoor speakers, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering. The company operates two operating segments: hearing enhancement and protection, and hair and skin care.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.